Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.

作者: Michael T. Deavers , Emily Tarco , Lavinia P. Middleton , Nour Sneige , Pamela Puig

DOI: 10.1043/1543-2165-133.5.775

关键词:

摘要: Abstract Context.—The American Society of Clinical Oncology/ College Pathologists (ASCO/CAP) guideline recommendations from January 2007 identified many sources immunohistochemistry (IHC) testing variation. Objective.—In this current study, we implemented the guidelines and addressed our institution's preanalytic, analytic, postanalytic variables relating to HER2 improve clinical outcomes. Design.—We evaluated core biopsies performed on breast lesions 2006 through 2007. Prognostic/predictive markers obtained by IHC were correlated with fluorescence in situ hybridization (FISH). Preanalytic biopsy variation studied collecting data number that needed repeat because inconclusive FISH results. Results.—In year preceding implementation guidelines, concordance was 98%. In an additional 10.8% cases, results inconclusive. When material became available re...

参考文章(13)
Mai P. Hoang, Aysegul A. Sahin, Nelson G. Ordòñez, Nour Sneige, HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. American Journal of Clinical Pathology. ,vol. 113, pp. 852- 859 ,(2000) , 10.1309/VACP-VLQA-G9DX-VUDF
P. C. Roche, V. J. Suman, R. B. Jenkins, N. E. Davidson, S. Martino, P. A. Kaufman, F. K. Addo, B. Murphy, J. N. Ingle, E. A. Perez, Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831 Journal of the National Cancer Institute. ,vol. 94, pp. 855- 857 ,(2002) , 10.1093/JNCI/94.11.855
S. Paik, J. Bryant, E. Tan-Chiu, E. Romond, W. Hiller, K. Park, A. Brown, G. Yothers, S. Anderson, R. Smith, D. L. Wickerham, N. Wolmark, Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. Journal of the National Cancer Institute. ,vol. 94, pp. 852- 854 ,(2002) , 10.1093/JNCI/94.11.852
Charles L Vogel, Melody A Cobleigh, Debu Tripathy, John C Gutheil, Lyndsay N Harris, Louis Fehrenbacher, Dennis J Slamon, Maureen Murphy, William F Novotny, Michael Burchmore, Steven Shak, Stanford J Stewart, Michael Press, Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 20, pp. 719- 726 ,(2002) , 10.1200/JCO.20.3.719
Neal S. Goldstein, Monica Ferkowicz, Eva Odish, Anju Mani, Farnaz Hastah, Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma American Journal of Clinical Pathology. ,vol. 120, pp. 86- 92 ,(2003) , 10.1309/QPHDRB00QXGMUQ9N
D. Slamon, G. Clark, S. Wong, W. Levin, A Ullrich, W. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science. ,vol. 235, pp. 177- 182 ,(1987) , 10.1126/SCIENCE.3798106
Melody A. Cobleigh, Charles L. Vogel, Debu Tripathy, Nicholas J. Robert, Susy Scholl, Louis Fehrenbacher, Janet M. Wolter, Virginia Paton, Steven Shak, Gracie Lieberman, Dennis J. Slamon, Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease Journal of Clinical Oncology. ,vol. 17, pp. 2639- 2648 ,(1999) , 10.1200/JCO.1999.17.9.2639